Lantheus Hldg

Stock

ISIN: US5165441032

Ticker: LNTH

US5165441032

LNTH

Price

Debate sobre LNTH

Puestos

ZeissJessy

@ZeissJessy

4Lun·

$PTP (-6,18 %) Pentixapharm,

What exactly is the company that was spun off from Eckert and Ziegler? $EUZ (-2,2 %) was spun off?

Andreas Eckert - founder of Eckert on this:

4 active ingredients including 2 in phase III and 2 in I/IIa

Target 2027 to bring both phase III diagnostics to market with EUR 55m expenditure.

However, further financing measures are required here.

20.8 million shares + 3.9 million in free float.

Other competitors in the market are

Telix Pharma and $TLX (+10,74 %)

Lantheus Holding $LNTH (-2,83 %)

1 Comentario

ThemenmitKopf@topicswithhead

4Lun

According to the venture probability valuation, the company value is around 100 to 150 million euros. I would actually like to get in, but statistically the share price is likely to fall even further. In addition, biotech has never really been in demand on the German stock exchange, which could lead to further setbacks. That really annoys me, because the share will easily slip below the 4-euro mark and I still don't know whether the bottom has been reached

•

Seventrader

@7Trader

5Lun·

New addition to the depot

$LNTH (-2,83 %)
Lantheus Holdings

EUR 6.59 bn market cap

P/E RATIO 18

2-digit earnings growth forecast for the coming years

Broadly speaking, the company is involved in radiopharmaceutical oncology and precision diagnostics, etc.

The radiopharmaceutical oncology products support medical professionals in detecting, combating and monitoring cancer.

Dis precision diagnostics products help healthcare professionals detect and track diseases at an early stage - when it matters most.

In addition to diagnostic products, there are also therapeutic products and some in the pipeline.

Many of you will come into contact with the products at an older age (although I wouldn't wish it on anyone). Be it because of prostate cancer or to visualize the coronary arteries during a check-up.